Tag: Alzheimer’s disease

1. Lower RBFOX1 was associated with greater amyloid burden in the prefrontal cortex. 2. Reduced RBFOX1 was associated with increased rate of decline and reduced neurocognitive performance, and may be a novel locus for preclinical and early Alzheimer’s disease. Evidence Rating Level: 1 (Excellent) Study Rundown: Genome-wide association studies (GWAS) have identified greater...

Association of a Care Bundle for Early Sepsis Management With Mortality Among Patients With Hospital-Onset or Community-Onset Sepsis 1. Sepsis bundles were not significantly associated with decreased risk of mortality or reduced vasopressor treatment time in community- or hospital-onset sepsis. 2. Components of the SEP-1 bundle, such as broad-spectrum IV antibiotic...

1. There is a significantly increased risk of dementia in patients with previously diagnosed depression, with the highest risk observed in patients diagnosed with severe depression Evidence Level: 2 (Good) The prevalence of dementia is on the rise. With a scarcity of effective treatment options, increased emphasis has been placed on the...

1. Flortaucipir-PET and CSF modalities for assessing tau pathology not only differ in results in early Alzheimer’s dementia (AD) but suprathreshold CSF P-tau may be indicative of early AD that is unrecognizable via cognitive testing. 2. CSF P-tau may provide evidence of disease progression that early fortaucipir-PET cannot sufficiently detect. Evidence...

Electronic Cigarette and JUUL Use Among Adolescents and Young Adults 1. The use of electronic cigarettes is highly prevalent among adolescents and young adults through the advent of JUUL, which has unique implications for this young and susceptible age group. Evidence Rating Level: 1 (Excellent) Adverse effects of nicotine on overall health,...

1. While well-tolerated in early and mild Alzheimer’s disease, the BACE1 inhibitor lanabecestat was generally ineffective in slowing cognitive and functional decline. Evidence Rating Level: 1 (Excellent) Amyloid plaques and neurofibrillary tangles are defining pathological characteristics of Alzheimer’s disease (AD). Inhibitors of the beta-site APP-cleaving enzyme 1 (BACE1) may reduce the...

1. While well-tolerated in early and mild Alzheimer’s disease, the BACE1 inhibitor lanabecestat was generally ineffective in slowing cognitive and functional decline. Evidence Rating Level: 1 (Excellent) Amyloid plaques and neurofibrillary tangles are defining pathological characteristics of Alzheimer’s disease (AD). Inhibitors of the beta-site APP-cleaving enzyme 1 (BACE1) may reduce the...

Association of Anticoagulant Therapy With Risk of Fracture Among Patients With Atrial Fibrillation 1. Direct oral anticoagulants, specifically apixaban, were associated with lower risk of fracture in patients with atrial fibrillation compared to warfarin. Evidence Rating Level: 2 (Good) Warfarin is commonly used to prevent cardioembolic events in individuals with atrial fibrillation...

Selective Vulnerability of the Nucleus Basalis of Meynert Among Neuropathologic Subtypes of Alzheimer Disease 1. Widespread cholinergic deficits found in early-onset Alzheimer’s disease (AD) may be a result of neurofibrillary tangle accumulation in the nucleus basalis of Meynert, specifically in those with hippocampal sparing AD. Evidence Rating Level: 1 (Excellent) The nucleus basalis...

Odanacatib for the Treatment of Postmenopausal Osteoporosis: Results of the LOFT Multicentre, Randomised, Double-Blind, Placebo-Controlled Trial and LOFT Extension Study 1. The cathepsin K inhibitor odanacatib reduced the risk of fracture but was associated with significantly increased risk of cardiovascular events, specifically stroke, in postmenopausal women with osteoporosis compared to...